Purespring Therapeutics has raised £80 million in an oversubscribed Series B financing
LONDON: Syncona Ltd’s portfolio company Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases has raised £80 million in...
Syncona launches Beacon Therapeutics with £96 million financing to develop ophthalmic gene therapies
LONDON, UK: London-based healthcare company Syncona Ltd has announced the launch of Beacon Therapeutics Holdings Limited (Beacon Therapeutics), a leading ophthalmic gene therapy company. The...